|
Reparixin
- 英文名称:Reparixin
- 品牌:WYTSCI
- 产地:进口
- 型号:1MG
- 货号:WT-AY-B10716
- cas:266359-83-5
- 价格: ¥1/mg
- 发布日期: 2025-04-10
- 更新日期: 2025-12-08
产品详请
| 产地 | 进口 |
| 品牌 | WYTSCI |
| 货号 | WT-AY-B10716 |
| 用途 | 科研检测 |
| 英文名称 | Reparixin |
| 包装规格 | 1MG |
| CAS编号 | 266359-83-5 |
| 别名 | Reparixin |
| 纯度 | 98+% |
| 分子式 | |
| 是否进口 | 是 |
纯度:99% by HPLC;NMR (Conforms)
分子式:C14H21NO3S
分子量:283.39
溶剂:DMSO (100 mg/ml) Ethanol (25 mg/ml)
性状:White solid
存储:-20°C
Activity (short version):CXCR 1/2 allosteric antagonist
Function / Pharmacology:Reparixin is a noncompetitive allosteric inhibitor of IL-8 (CXCL8) activation of CXCR1 and CXCR2 chemokine receptors (IC50 = 1 and 100 nM, respectively). It blocks a number of activities related to IL-8 signaling, including leukocyte recruitment (IC50 = 1 nM) without affecting receptor activation induced by other CXCR1 and CXCR2 agonists.1 In spontaneously hypertensive rats, 5 mg/kg reparixin administered daily for three weeks was shown to reduce blood pressure by inhibiting hypertension-related mediators.2 It attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord.3 Reparixin blockade (100 nM) of CXCR1 has also been used to deplete a cancer stem cell population in human breast cancer cell lines in vitro.4
分子式:C14H21NO3S
分子量:283.39
溶剂:DMSO (100 mg/ml) Ethanol (25 mg/ml)
性状:White solid
存储:-20°C
Activity (short version):CXCR 1/2 allosteric antagonist
Function / Pharmacology:Reparixin is a noncompetitive allosteric inhibitor of IL-8 (CXCL8) activation of CXCR1 and CXCR2 chemokine receptors (IC50 = 1 and 100 nM, respectively). It blocks a number of activities related to IL-8 signaling, including leukocyte recruitment (IC50 = 1 nM) without affecting receptor activation induced by other CXCR1 and CXCR2 agonists.1 In spontaneously hypertensive rats, 5 mg/kg reparixin administered daily for three weeks was shown to reduce blood pressure by inhibiting hypertension-related mediators.2 It attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord.3 Reparixin blockade (100 nM) of CXCR1 has also been used to deplete a cancer stem cell population in human breast cancer cell lines in vitro.4



